Connect with us

Business

WHO study finds no benefit from remdesivir on COVID-19 deaths, hospital stays | TheHill – The Hill

The antiviral drug remdesivir had no substantial impact on the survival of COVID-19 patients or the length of their hospital stays, according to a World Health …

Published

on

post featured image
ADVERTISEMENT

The antiviral drug remdesivir had no substantial impact on the survival of COVID-19 patients or the length of their hospital stays, according to a World Health Organization (WHO) clinical trial.
The results, announced late Thursday, could potentially be a major blow to the efforts of finding a suitable treatment to the disease that has killed more than 217,000 Americans.
The WHO Solidarity Trial examined the effects of four coronavirus different drug regimens: remdesivir; hydroxychloroquine; a…

Click here to view the original article.

You might also like ...

post featured image
First adults-only casino in Vegas is now open with the world’s largest sports book – The Points Guy
post featured image
Bed Bath & Beyond overhauls strategy after closings, layoffs – Fox Business
post featured image
Dow Jones Plunges As Coronavirus Cases Soar, GE Stock A Rare Winner – Investor’s Business Daily